BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (ORIGINAL MARKET DATE)

Omvoh™/Eli Lilly and Company/LillyPlus® (2023)

APPROVED CLINICAL INDICATIONS

(may vary within provinces – refer to local patient support program)

Ulcerative colitis

CLASS

Interleukin-23 (IL-23) p 19 antagonist

ACTION

Humanized immunoglobulin G4 (IgG4) monoclonal antibody that binds with high affinity and specificity to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor.